MY210469A - Pcsk9 inhibitors and methods of use thereof - Google Patents
Pcsk9 inhibitors and methods of use thereofInfo
- Publication number
- MY210469A MY210469A MYPI2021003994A MYPI2021003994A MY210469A MY 210469 A MY210469 A MY 210469A MY PI2021003994 A MYPI2021003994 A MY PI2021003994A MY PI2021003994 A MYPI2021003994 A MY PI2021003994A MY 210469 A MY210469 A MY 210469A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- pcsk9 inhibitors
- pcsk9
- inhibitors
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962794239P | 2019-01-18 | 2019-01-18 | |
| PCT/US2020/013882 WO2020150474A1 (en) | 2019-01-18 | 2020-01-16 | Pcsk9 inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY210469A true MY210469A (en) | 2025-09-24 |
Family
ID=71608564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021003994A MY210469A (en) | 2019-01-18 | 2020-01-16 | Pcsk9 inhibitors and methods of use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11603523B2 (en) |
| EP (2) | EP3911640B1 (en) |
| JP (2) | JP2022518016A (en) |
| KR (2) | KR20210116549A (en) |
| CN (1) | CN113412258A (en) |
| AU (3) | AU2020209216A1 (en) |
| BR (1) | BR112021013924A2 (en) |
| CA (1) | CA3125767A1 (en) |
| EA (1) | EA202191890A1 (en) |
| IL (1) | IL284661A (en) |
| MA (1) | MA54758A (en) |
| MX (2) | MX2021008661A (en) |
| MY (1) | MY210469A (en) |
| SG (1) | SG11202107615TA (en) |
| TW (1) | TWI921300B (en) |
| WO (1) | WO2020150474A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021013924A2 (en) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | PCSK9 INHIBITORS AND METHODS OF USING THEM |
| WO2020150473A2 (en) * | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| CN113248501B (en) * | 2021-06-17 | 2021-10-08 | 南京韦尔优众医药有限公司 | CLY series compounds, preparation method thereof and application thereof in preparing medicines |
| CN113735846A (en) * | 2021-10-11 | 2021-12-03 | 河北师范大学 | Benzothiazole derivative and medical application thereof |
| WO2023084449A1 (en) * | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| TW202329937A (en) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | Bicyclic amine cdk12 inhibitors |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| US20240217951A1 (en) * | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| US20240228469A1 (en) | 2022-09-23 | 2024-07-11 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN121913991A (en) * | 2022-10-14 | 2026-04-24 | 上海翰森生物医药科技有限公司 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof |
| CN119264042A (en) * | 2023-07-04 | 2025-01-07 | 上海翰森生物医药科技有限公司 | Cyclopentane derivative inhibitor, preparation method and application thereof |
| CN121443616A (en) | 2023-07-27 | 2026-01-30 | 上海拓界生物医药科技有限公司 | Diaminocyclopentyl-substituted heteroaryl derivatives, their uses and preparation methods |
| TW202547505A (en) | 2024-02-05 | 2025-12-16 | 瑞典商阿斯特捷利康公司 | Pharmaceutical compositions comprising azd0780 |
| TW202545529A (en) | 2024-02-05 | 2025-12-01 | 瑞典商阿斯特捷利康公司 | Combination therapy |
| WO2025183455A1 (en) * | 2024-02-29 | 2025-09-04 | 재단법인 대구경북첨단의료산업진흥재단 | Benzoxazole derivatives as pcsk9 inhibitor |
| TW202539678A (en) * | 2024-03-20 | 2025-10-16 | 瑞典商阿斯特捷利康公司 | Pcsk9 inhibitors and methods of use thereof |
| WO2025214500A1 (en) * | 2024-04-12 | 2025-10-16 | 上海翰森生物医药科技有限公司 | Free base crystal form of nitrogen-containing heterocyclic derivative, acid salt and crystal form thereof, preparation method therefor, and use thereof |
| TW202612699A (en) | 2024-05-16 | 2026-04-01 | 瑞典商阿斯特捷利康公司 | Combination therapy |
| WO2026021380A1 (en) * | 2024-07-22 | 2026-01-29 | 深圳信立泰药业股份有限公司 | Pcsk9 and hmg-coa dual-target compound and use thereof |
| WO2026026878A1 (en) * | 2024-07-30 | 2026-02-05 | 成都施贝康生物医药科技有限公司 | Heterocyclic derivative inhibitor, and preparation thereof and use thereof |
| WO2026086805A1 (en) * | 2024-10-23 | 2026-04-30 | 深圳信立泰药业股份有限公司 | Pcsk9 and hmg-coa bicyclic compound, and preparation and use thereof |
| WO2026092600A1 (en) * | 2024-10-31 | 2026-05-07 | 石药集团中奇制药技术(石家庄)有限公司 | Nitrogen-containing heterocyclic compound and use thereof |
| WO2026093543A1 (en) | 2024-11-01 | 2026-05-07 | Astrazeneca Ab | Glp1r agonist and pcsk9 inhibitor combination therapy |
| WO2026092659A1 (en) * | 2024-11-01 | 2026-05-07 | 盛睿泽华医药科技(苏州)有限公司 | Polycyclic compound, preparation method therefor, and use thereof |
| WO2026131688A2 (en) * | 2024-12-16 | 2026-06-25 | Astrazeneca Ab | Crystalline forms and methods of synthesis |
| WO2026145737A1 (en) * | 2025-01-03 | 2026-07-09 | 江苏豪森药业集团有限公司 | Salt of class of nitrogen-containing heterocyclic derivatives and crystal form thereof, preparation method therefor, and use thereof |
| WO2026158426A1 (en) * | 2025-01-23 | 2026-07-30 | 江苏恒瑞医药股份有限公司 | Crystal forms of diaminocyclopentyl-substituted heteroaryl derivative and preparation method therefor |
| WO2026158425A1 (en) * | 2025-01-23 | 2026-07-30 | 江苏恒瑞医药股份有限公司 | Pharmaceutically acceptable salt of diaminocyclopentyl-substituted heteroaryl derivative, crystalline form thereof, and use thereof |
| WO2026158633A1 (en) * | 2025-01-27 | 2026-07-30 | 乐普(北京)医疗器械股份有限公司 | Nitrogen-containing heterocyclic compound small-molecule inhibitor and use thereof |
Family Cites Families (197)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| CA2192203A1 (en) | 1994-06-17 | 1995-12-28 | Werner Hofheinz | N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials |
| AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| GB9526546D0 (en) | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
| SE9603285D0 (en) | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
| DE69818675T2 (en) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | GALACTOMANAN POLYMERS AND BORATE CONTAINING EYE MEDICINAL PRODUCTS |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| US20040138284A1 (en) | 2000-02-11 | 2004-07-15 | Matthias Wiesner | Indol-3-yl derivatives |
| GB0014022D0 (en) | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
| WO2002020500A2 (en) | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| AU2002341693B2 (en) | 2001-09-21 | 2008-05-29 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
| JP2005519895A (en) | 2002-01-18 | 2005-07-07 | ファルマシア・コーポレーション | Substituted pyridazinones as P38 inhibitors |
| WO2003099276A1 (en) | 2002-05-10 | 2003-12-04 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
| WO2004017920A2 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
| US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| CA2510793A1 (en) | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| US20050197350A1 (en) | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| WO2004094471A2 (en) | 2003-04-22 | 2004-11-04 | Avanir Pharmaceuticals | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| MXJL06000069A (en) * | 2004-06-09 | 2007-04-10 | Avanir Pharmaceuticals | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases. |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| JP2008514546A (en) | 2004-09-30 | 2008-05-08 | 大正製薬株式会社 | Pyridine derivatives and therapies associated with their use |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| EP1814856A1 (en) | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| CA2598043A1 (en) | 2005-02-25 | 2006-08-31 | Rigel Pharmaceuticals, Inc. | Benzisothiazoles useful for treating or preventing hcv infection |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| EA015890B1 (en) | 2005-06-14 | 2011-12-30 | Тайджен Байотекнолоджи Ко. Лтд. | Pyrimidine compounds |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| JP2007291087A (en) | 2006-03-29 | 2007-11-08 | Taisho Pharmaceut Co Ltd | Pyridine derivatives and therapies associated with their use |
| EP2502918B1 (en) | 2006-07-25 | 2015-03-25 | Cephalon, Inc. | Pyridazinone Derivatives |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| EP2121619A2 (en) | 2006-11-24 | 2009-11-25 | AC Immune S.A. | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| WO2008072963A1 (en) | 2006-12-13 | 2008-06-19 | Givaudan Nederland Services B.V. | Flavour modulating derivative of a carboxylic acid and a purine, pyrimidine, nucleoside or nucleotide |
| CN102232088A (en) * | 2007-10-26 | 2011-11-02 | 先灵公司 | Anti-PCSK9 and methods for treating lipid and cholesterol disorders |
| US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CN107233337A (en) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | Pharmaceutical composition containing EPA and cardiovascular agents and use its method |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| RU2012104214A (en) | 2009-08-05 | 2013-09-10 | Верситек Лимитед | ANTIVIRAL COMPOUNDS AND METHODS FOR PRODUCING AND USING THEM |
| US8952037B2 (en) | 2010-05-13 | 2015-02-10 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
| WO2011147199A1 (en) | 2010-05-28 | 2011-12-01 | Versitech Limited | Compounds and methods for treating viral infections |
| KR20130111512A (en) | 2010-06-04 | 2013-10-10 | 코와 가부시키가이샤 | Optically active dibenzylamine derivatives and preparation methods thereof |
| CA2802952A1 (en) | 2010-06-24 | 2011-12-29 | Arisaph Pharmaceuticals, Inc. | Niacin mimetics, and methods of use thereof |
| AU2011270719B2 (en) | 2010-06-24 | 2015-09-24 | Arisaph Pharmaceuticals, Inc. | Niacin mimetics, and methods of use thereof |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| WO2012101062A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| AU2012258618B2 (en) | 2011-05-26 | 2017-05-25 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptors 5 modulators and methods of use thereof |
| US8815909B2 (en) | 2011-07-18 | 2014-08-26 | Bristol-Myers Squibb Company | Diaminocyclohexane compounds and uses thereof |
| JP5741850B2 (en) | 2011-09-13 | 2015-07-01 | コニカミノルタ株式会社 | Optical film, polarizing plate including the same, and liquid crystal display device |
| JP6295205B2 (en) | 2012-01-06 | 2018-03-14 | ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. | How to reduce the risk of cardiovascular disease |
| TW201348231A (en) | 2012-02-29 | 2013-12-01 | Amgen Inc | Heterobicyclic compounds |
| US9567316B2 (en) | 2012-03-07 | 2017-02-14 | The Mclean Hospital Corporation | Aminoquinoline derivatives and uses thereof |
| WO2013137371A1 (en) | 2012-03-15 | 2013-09-19 | 興和株式会社 | Novel pyrimidine compound and medicine comprising same |
| US9658211B2 (en) | 2012-04-18 | 2017-05-23 | Hemoshear, Llc | In vitro model for pathological or physiologic conditions |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| WO2013177536A2 (en) | 2012-05-25 | 2013-11-28 | Catabasis Pharmaceuticals, Inc. | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| US9434695B2 (en) | 2012-07-18 | 2016-09-06 | Sunshine Lake Pharma Co., Ltd | Nitrogenous heterocyclic derivatives and their application in drugs |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| AR092924A1 (en) | 2012-10-09 | 2015-05-06 | Sanofi Sa | PIRROLIDINONE DERIVATIVES AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| US10059671B2 (en) | 2013-02-04 | 2018-08-28 | Prexton Therapeutics Sa | Positive allosteric modulators of mGluR3 |
| TWI644899B (en) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap modulators |
| RS62649B1 (en) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Dna-pk inhibitors |
| CN105143203A (en) | 2013-04-17 | 2015-12-09 | 辉瑞大药厂 | N-piperidin-3-ylbenzamide derivatives for the treatment of cardiovascular diseases |
| TWI682780B (en) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | Use of a pharmaceutical composition for the manufacture of a medicament for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations |
| TW201534324A (en) | 2013-06-07 | 2015-09-16 | Sanofi Sa | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| AR092240A1 (en) | 2013-08-26 | 2015-04-08 | Sunshine Lake Pharma Co Ltd | NITROGEN HETEROCICLIC DERIVATIVES AND ITS APPLICATION IN PHARMACOS |
| US10010588B2 (en) | 2013-08-30 | 2018-07-03 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating hyperlipidemia |
| MX373298B (en) | 2013-10-11 | 2020-05-20 | Sanofi Biotechnology | USE OF A PCSK9 INHIBITOR TO TREAT HYPERLIPIDEMIA. |
| CN104558685B (en) | 2013-10-24 | 2017-09-29 | 中国石油化工股份有限公司 | A kind of phosphorus nitrogen expansion type combustion inhibitor and its synthetic method |
| JP2017019724A (en) | 2013-10-25 | 2017-01-26 | 第一三共株式会社 | Substituted pyridine compounds and other pharmaceutical combinations |
| WO2015086723A2 (en) | 2013-12-11 | 2015-06-18 | Glycotope Gmbh | Glycosylated glycophorin peptides |
| TW201609798A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609797A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| CU24395B1 (en) | 2014-03-17 | 2019-04-04 | Pfizer | DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS |
| AR099937A1 (en) | 2014-04-04 | 2016-08-31 | Sanofi Sa | ISOINDOLINONE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS |
| RU2016143092A (en) | 2014-04-04 | 2018-05-08 | Санофи | SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR TREATING DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS |
| AR099936A1 (en) | 2014-04-04 | 2016-08-31 | Sanofi Sa | CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| EP3148537B1 (en) | 2014-05-30 | 2018-09-26 | Université Paris Descartes | Cyclic compounds having a 1,3 diamino-functionality for use in the treatment of hiv infection |
| WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI744723B (en) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | Synthesis of polycyclic-carbamoylpyridone compounds |
| AU2015289617B2 (en) | 2014-07-16 | 2021-04-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2016054388A1 (en) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Glutaminase inhibitors |
| ES2907461T3 (en) | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds, compositions and methods of use thereof |
| US20180000793A1 (en) | 2015-02-06 | 2018-01-04 | Ernesto Abel-Santos | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis |
| AR103954A1 (en) | 2015-03-18 | 2017-06-14 | Zealand Pharma As | AMILINE ANALOGS |
| EP3271405A1 (en) | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
| PL3283507T3 (en) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylated glucagon analogue |
| MX2018005096A (en) | 2015-11-06 | 2018-08-15 | Gemphire Therapeutics Inc | Gemcabene combinations for the treatment of cardiovascular disease. |
| TW201731867A (en) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | FGF21 variant |
| EP4085934A1 (en) | 2015-12-11 | 2022-11-09 | The Trustees of The University of Pennsylvania | Gene therapy for treating familial hypercholesterolemia |
| BR112018014794A2 (en) | 2016-01-20 | 2018-12-11 | Janssen Sciences Ireland Uc | aryl substituted pyrimidines for use in influenza virus infection |
| SG10201912756XA (en) | 2016-02-26 | 2020-02-27 | Gemphire Therapeutics Inc | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| CA3020087A1 (en) | 2016-04-14 | 2017-10-19 | Michael LUCEY | Combinational compositions and methods of use thereof |
| TW201808888A (en) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US10960020B2 (en) | 2016-09-15 | 2021-03-30 | The Brigham And Women's Hospital, Inc. | Modulation of PCSK9 and LDLR through DRP1 inhibition |
| HRP20240930T1 (en) | 2016-10-18 | 2024-10-11 | Novartis Ag | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
| KR20240044543A (en) | 2016-11-10 | 2024-04-04 | 시에스엘 리미티드 | Reconstituted high density lipoprotein treatment of myocardial infarction |
| JOP20190112A1 (en) | 2016-11-14 | 2019-05-14 | Amgen Inc | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| MA48602A (en) | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | HETEROARYL COMPOUNDS SUBSTITUTED BY AN ALKYL PHOSPHINE OXIDE AMIDE AS MODULATORS OF IL-12, IL-23 AND / OR IFN ALPHA RESPONSES |
| EP3579782B1 (en) | 2017-02-08 | 2024-05-01 | Brooke Schumm | Intra-operative radiation therapy capsule with cylindrical shell radiation containment shutter system |
| SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| AR110988A1 (en) | 2017-02-21 | 2019-05-22 | Sanofi Sa | AZETIDINE COMPOUNDS AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS |
| EP3609882B1 (en) | 2017-03-17 | 2022-07-13 | Cardio Therapeutics Pty Ltd | Heterocyclic inhibitors of pcsk9 |
| CN110691779B (en) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | Approaches to Treating Hematologic Malignancies and Ewing's Sarcoma |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN110831593A (en) | 2017-06-14 | 2020-02-21 | 特维娜有限公司 | Compounds for modulating S1P1 activity and methods of using the same |
| JP6928986B2 (en) | 2017-06-26 | 2021-09-01 | 深▲チェン▼市塔吉瑞生物医薬有限公司Shenzhen TargetRx, Inc. | Indazole compounds, compositions and uses thereof for inhibiting kinase activity |
| CN109384712B (en) | 2017-08-14 | 2021-05-07 | 北京宽厚医药科技有限公司 | NK1 receptor targeting antagonist and application thereof in treatment of nausea and vomiting caused by chemotherapy |
| EP3676268A1 (en) | 2017-10-20 | 2020-07-08 | Dana-Farber Cancer Institute, Inc. | Heterobifunctional compounds with improved specificityfor the bromodomain of brd4 |
| US11400082B2 (en) | 2017-10-30 | 2022-08-02 | Montréal Heart Institute | Methods of treating elevated plasma cholesterol |
| CN111315772A (en) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | anti-APOC 3 antibodies and methods of use thereof |
| UY37957A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
| MY202167A (en) | 2017-11-21 | 2024-04-12 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| WO2019111225A1 (en) | 2017-12-08 | 2019-06-13 | Avaliv Therapeutics | Compounds and methods for the treatment of non‑alcoholic steatohepatitis |
| SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| BR112020014140A2 (en) * | 2018-01-17 | 2020-12-01 | Vertex Pharmaceuticals Incorporated | dna-pk inhibitors |
| US11513131B2 (en) | 2018-01-22 | 2022-11-29 | Global Genomics Group, LLC | Low density lipoprotein triglycerides (LDL-TG) as a biomarker of cardiovascular disease and uses thereof |
| US11911445B2 (en) | 2018-01-23 | 2024-02-27 | Gila Therapeutics, Inc. | Peptide YY pharmaceutical formulations, compositions, and methods |
| US20210324067A9 (en) | 2018-03-09 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Combination therapy for cardiovascular diseases |
| JP7485609B2 (en) | 2018-03-22 | 2024-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | Pyridine-Containing Heterocyclic Compounds Useful as Modulators of IL-12, IL-23 and/or IFNα Responses - Patent application |
| CN110384801B (en) | 2018-04-20 | 2021-09-14 | 中国科学院上海药物研究所 | Application of miRNA552 cluster microRNA in treatment of LDLC related metabolic diseases |
| EP3784669B1 (en) | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
| US20190374526A1 (en) | 2018-06-06 | 2019-12-12 | Merck Sharp & Dohme Corp. | Substituted Heterocyclic Compounds as Inhibitors of PRDM9 |
| US11442072B2 (en) | 2018-07-10 | 2022-09-13 | Jenny and Antti Wihuri Foundation | Method for measuring LDL aggregation |
| JP7161605B2 (en) | 2018-08-31 | 2022-10-26 | ファイザー・インク | Combinations for the treatment of NASH/NAFLD and related disorders |
| JP2022504287A (en) | 2018-10-03 | 2022-01-13 | スターテン・バイオテクノロジー・ベー・フェー | Antibodies specific for human and cynomolgus monkey APOC3, and methods of their use |
| RS66346B1 (en) | 2018-10-22 | 2025-01-31 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| JP2022512911A (en) | 2018-11-09 | 2022-02-07 | ノバルティス アーゲー | Methods of reducing the risk of cardiovascular events using conjugated antisense compounds that target apo (a) |
| WO2020115288A1 (en) | 2018-12-06 | 2020-06-11 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| BR112021013924A2 (en) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | PCSK9 INHIBITORS AND METHODS OF USING THEM |
| WO2020150473A2 (en) * | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| CN111484480B (en) | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | Polycyclic derivative inhibitor, preparation method and application thereof |
| CA3128368A1 (en) | 2019-02-01 | 2020-08-06 | Memorial Sloan Kettering Cancer Center | Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker |
| AU2020260110A1 (en) | 2019-04-17 | 2021-11-11 | Ngm Biopharmaceuticals, Inc. | Combination therapy for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| JP2023506732A (en) | 2019-12-10 | 2023-02-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Use of PCSK9 inhibitors to treat homozygous familial hypercholesterolemia |
| WO2021209808A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
| CN113713107B (en) | 2020-05-26 | 2022-09-23 | 中国科学院上海药物研究所 | Application of miRNA552 cluster microRNA in treatment of glycolipid metabolic disease |
| WO2021243002A1 (en) | 2020-05-29 | 2021-12-02 | Amgen Inc. | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders |
| MX2022015517A (en) | 2020-06-10 | 2023-01-16 | Ferring Bv | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATEROSCLEROTIC CARDIOVASCULAR DISEASE. |
| US20240002354A1 (en) | 2020-08-05 | 2024-01-04 | Rezubio Pharmaceuticals Co., Ltd | Antidiabetic compounds and compositions |
| WO2022029334A1 (en) | 2020-08-07 | 2022-02-10 | Gbiotech S.À.R.L. | Combination therapies for treating coronavirus infection |
| JP7824930B2 (en) | 2020-08-19 | 2026-03-05 | バイオジェン・エムエイ・インコーポレイテッド | Treatment of hypercholesterolemia |
| BR112023004716A2 (en) | 2020-09-15 | 2023-05-09 | Regeneron Pharma | USE OF LEPR AGONISTS FOR PAIN |
| US20240158382A1 (en) | 2020-10-20 | 2024-05-16 | Gbiotech S. A. R. L. | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor |
| KR20230104200A (en) | 2020-11-05 | 2023-07-07 | 암젠 인크 | Methods of treating atherosclerotic cardiovascular disease using LPA-targeted RNAi constructs |
| IL303130A (en) | 2020-12-11 | 2023-07-01 | Helsingin Yliopisto | Method for determining a likelihood of a subject to respond to lipid lowering therapy |
| EP4011877A3 (en) | 2020-12-11 | 2023-01-11 | Institut de Cardiologie de Montréal | Method of treating elevated plasma cholesterol |
| JP2024512255A (en) | 2021-02-22 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods for diagnosing and treating partial lipoatrophy |
| US20250281495A1 (en) | 2021-02-25 | 2025-09-11 | Icahn School Of Medicine At Mount Sinai | Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease |
| AU2022248850A1 (en) | 2021-03-27 | 2023-11-09 | TRx Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| US12612626B2 (en) | 2021-06-24 | 2026-04-28 | Sirnaomics, Inc. | siRNA compound that inhibits expression of APOC3 |
| MX2023015442A (en) | 2021-06-25 | 2024-03-12 | Amgen Inc | Treatment of cardiovascular disease with trem-1 antigen binding proteins. |
| WO2023285583A1 (en) | 2021-07-14 | 2023-01-19 | Eternygen Uk Ltd. | 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives for use in the treatment of diseases responsive to citrate transporter modulation |
| WO2023052783A1 (en) | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
| TW202325288A (en) | 2021-11-05 | 2023-07-01 | 英商喜翠克斯治療有限公司 | Novel compounds |
| EP4446307A4 (en) | 2021-11-12 | 2025-12-10 | Shenzhen Jingtai Tech Co Ltd | Derivative of asparagic acid and its use in the treatment of metabolic disorders such as liver fibrosis and non-alcoholic hepatitis |
| CN114277032A (en) | 2021-12-31 | 2022-04-05 | 华中科技大学同济医学院附属协和医院 | Low-density lipoprotein receptor gene mutant and application thereof |
| KR20240134933A (en) | 2022-01-14 | 2024-09-10 | 레주바이오 파마슈티칼스 컴퍼니 리미티드 | Antidiabetic compounds and compositions |
| TW202345865A (en) | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | Composition and method for inhibiting expression of protein LPA(Apo(a)) |
| CN116617390A (en) | 2022-02-11 | 2023-08-22 | 武汉大学 | Application of ASGR1 inhibitors in promoting cholesterol efflux and treating nonalcoholic fatty liver disease |
| WO2023173004A2 (en) | 2022-03-11 | 2023-09-14 | University Of Florida Research Foundation, Incorporated | Targeting ptchd1 and neuronal cholesterol to enhance safety of opioid analgesics |
| US20230338419A1 (en) | 2022-03-21 | 2023-10-26 | The Trustees Of The University Of Pennsylvania | Methods and apparatus for diagnosis and detection of cardiac allograft vasculopathy |
| CN116948030B (en) | 2022-04-25 | 2024-11-19 | 武汉大学 | Anti-ASGR1 monoclonal antibody and its application |
| CN117045715B (en) | 2022-05-13 | 2025-06-06 | 浙江养生堂天然药物研究所有限公司 | Red apple and cherry plum composition and its application in anti-atherosclerosis |
| CN115581694A (en) | 2022-11-10 | 2023-01-10 | 正大青春宝药业有限公司 | Application of senkyunolide I in preparation of medicine for treating hyperlipidemia |
| CN117180404A (en) | 2023-10-24 | 2023-12-08 | 清华大学 | The use of cholesin in regulating cholesterol homeostasis |
| CN117482076A (en) | 2023-11-24 | 2024-02-02 | 中国人民解放军陆军军医大学第二附属医院 | Application of methionine compounds in the preparation of PCSK9 inhibitors |
-
2020
- 2020-01-16 BR BR112021013924-9A patent/BR112021013924A2/en unknown
- 2020-01-16 MY MYPI2021003994A patent/MY210469A/en unknown
- 2020-01-16 US US16/744,932 patent/US11603523B2/en active Active
- 2020-01-16 EA EA202191890A patent/EA202191890A1/en unknown
- 2020-01-16 SG SG11202107615TA patent/SG11202107615TA/en unknown
- 2020-01-16 KR KR1020217025811A patent/KR20210116549A/en not_active Ceased
- 2020-01-16 CA CA3125767A patent/CA3125767A1/en active Pending
- 2020-01-16 JP JP2021541180A patent/JP2022518016A/en not_active Withdrawn
- 2020-01-16 CN CN202080009277.4A patent/CN113412258A/en active Pending
- 2020-01-16 MA MA054758A patent/MA54758A/en unknown
- 2020-01-16 KR KR1020267002313A patent/KR20260035207A/en active Pending
- 2020-01-16 WO PCT/US2020/013882 patent/WO2020150474A1/en not_active Ceased
- 2020-01-16 EP EP20741354.3A patent/EP3911640B1/en active Active
- 2020-01-16 MX MX2021008661A patent/MX2021008661A/en unknown
- 2020-01-16 EP EP26170344.1A patent/EP4790054A2/en active Pending
- 2020-01-16 AU AU2020209216A patent/AU2020209216A1/en not_active Abandoned
- 2020-01-17 TW TW109101672A patent/TWI921300B/en active
-
2021
- 2021-07-06 IL IL284661A patent/IL284661A/en unknown
- 2021-07-16 MX MX2024009001A patent/MX2024009001A/en unknown
-
2023
- 2023-01-25 US US18/159,270 patent/US12584120B2/en active Active
- 2023-03-31 AU AU2023201972A patent/AU2023201972C1/en active Active
-
2025
- 2025-03-04 JP JP2025033599A patent/JP2025106240A/en active Pending
- 2025-04-24 AU AU2025202886A patent/AU2025202886A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3125767A1 (en) | 2020-07-23 |
| MA54758A (en) | 2022-04-27 |
| US20230407285A1 (en) | 2023-12-21 |
| EP3911640A4 (en) | 2022-10-26 |
| JP2025106240A (en) | 2025-07-15 |
| BR112021013924A2 (en) | 2021-09-21 |
| SG11202107615TA (en) | 2021-08-30 |
| AU2020209216A1 (en) | 2021-08-26 |
| CN113412258A (en) | 2021-09-17 |
| WO2020150474A1 (en) | 2020-07-23 |
| US20200231584A1 (en) | 2020-07-23 |
| JP2022518016A (en) | 2022-03-11 |
| US12584120B2 (en) | 2026-03-24 |
| KR20260035207A (en) | 2026-03-12 |
| MX2021008661A (en) | 2021-08-19 |
| US11603523B2 (en) | 2023-03-14 |
| EP3911640B1 (en) | 2026-05-13 |
| AU2023201972A1 (en) | 2023-05-04 |
| EP3911640A1 (en) | 2021-11-24 |
| TW202042817A (en) | 2020-12-01 |
| AU2023201972C1 (en) | 2025-10-23 |
| TWI921300B (en) | 2026-04-11 |
| IL284661A (en) | 2021-08-31 |
| EP4790054A2 (en) | 2026-08-12 |
| AU2023201972B2 (en) | 2025-02-13 |
| AU2025202886A1 (en) | 2025-05-15 |
| KR20210116549A (en) | 2021-09-27 |
| MX2024009001A (en) | 2024-07-31 |
| EA202191890A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009001A (en) | Pcsk9 inhibitors and methods of use thereof. | |
| PH12022551503A1 (en) | Kras mutant protein inhibitors | |
| IL284640A (en) | PCSK9 inhibitors and methods of using them | |
| IL286373A (en) | Protein tyrosine phosphatase inhibitor compounds and uses thereof | |
| DK3966207T3 (en) | PHENYLAMINOPYRIMIDINAMIDE AUTOPHAGY INHIBITORS AND METHODS OF USING THEREOF | |
| DK3966206T3 (en) | HETEROARYLAMINOPYRIMIDINAMIDE AUTOPHAGY INHIBITORS AND METHODS OF USING THEREOF | |
| MX2018013983A (en) | KRAS G12C INHIBITORS. | |
| IL308476A (en) | Inhibitors of the menin-mll interaction | |
| MA38828A1 (en) | Antibodies to plasminogen activator inhibitor type 1 (pai-1) and their uses | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| IL281451A (en) | Uses of Plasminogen Activator Inhibitor 1 (PAI-1) Inhibitors | |
| ZA202202245B (en) | Quinoline derivatives as protein kinase inhibitors | |
| IL291158A (en) | Iraq inhibitor and the method of preparation therefor and its use | |
| IL281450A (en) | Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses thereof | |
| EP4240363A4 (en) | 7-PHENYL-SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | |
| EP4333821A4 (en) | INHIBITORS OF SARS-COV-2 | |
| EA201790484A1 (en) | Derivatives of tetrahydroquinoline as bromodomain inhibitors | |
| EA202192575A1 (en) | DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT | |
| EA201892051A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MALIGNANT NON-FORMATION | |
| EP4240361A4 (en) | 7-AZOLE-SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | |
| JOP20230205A1 (en) | Vmat2 inhibitors and methods of use | |
| EP4384164A4 (en) | INHIBITORS OF HYPOXI-INDUCIBLE FACTORS | |
| EP4069229A4 (en) | SOLID STATE FORMS OF HDAC INHIBITOR | |
| EA201992200A1 (en) | MICROINCapsULATED NITRIFICATION INHIBITOR COMPOSITIONS | |
| IL291368A (en) | Inhibitor of metadherin expression |